Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company's most advanced ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

Detailed price information for Prelude Therapeutics Inc (PRLD-Q) from The Globe and Mail including charting and trades.

Keytruda accounted for $7.3 billion of the company’s $16.1 billion topline in Q2 2024 ... Merck has a lengthy pipeline with ...

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...

M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...

TX an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123, an anti-VISTA monoclonal antibody, as monotherapy and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA, in ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...